CLDI: Calidi Biotherapeutics Narx-foyda va o‘sish multiplikatori
Calidi Biotherapeutics innovatsion hujayra platformalarini yaratish uchun yetakchi hujayra biologlarini birlashtiradi. GURU.Markets terminalining chiziqli grafigidagi o'sishga nisbatan P/E tarixi baholash dinamikasini aks ettiradi, bunda 0.00 qiymati joriy ko'rsatkichni anglatadi. Calidi Biotherapeutics viruslarni o'smalarga yetkazib berishning aniq usullarini joriy etib, professional onkologiya hamjamiyatining chuqur ishonchini va uzoq muddatli investorlarning sodiqligini qozonmoqda.
Calidi Biotherapeutics (CLDI) kompaniyasining tahliliy kesimlari
- aksiya narxi va baholash bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- xususiy kapitalning balans qiymati ko'rsatkichlari:
- biznesning qarz tarkibi va likvidligi tafsilotlari:
Qarzning kapitalga nisbati Calidi Biotherapeutics|CLDI - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati calidibio.com|CLDI - Kompaniyaning jamlangan qarzlari|Balans kapitallashuviga qarzlar Calidi Bio|CLDI - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzi Calidi Biotherapeutics|Oraliq qoplama koeffitsiyenti calidibio.com
- kompaniyaning daromadliligi va baholash multiplikatorlari ko'rsatkichlari:
CLDI - Sof foyda|Sof foyda prognozi Calidi Biotherapeutics|CLDI - P/E multiplikatori|Kapitalizatsiyaning prognoz qilingan foydaga nisbati calidibio.com|CLDI - Narx-foyda va o‘sish multiplikatori|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Calidi Bio|CLDI - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bir aksiya uchun foyda Calidi Biotherapeutics|CLDI - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik o'zgarishi calidibio.com|CLDI - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yilda bir aksiya uchun sof foydaning kutilayotgan o'sishi Calidi Biotherapeutics
Kompaniyaning umumiy tahlili:CLDI Calidi Biotherapeutics Inc.
PEG koeffitsiyenti joriy P/E koeffitsiyentini foyda o'sish sur'atlari bilan solishtiradi, bunda birdan past qiymat aktivning kengayishiga nisbatan fundamental past baholanganligidan dalolat beradi. O'sishga nisbatan past baholanganlikning ushbu ko'rsatkichi tahlil qilish orqali, investor Calidi Biotherapeutics (CLDI) kompaniyasining bozor qiymatini onkolitik viruslarni stam hujayralari orqali o'smalarga yetkazib berish platformasining noyobligi prizmasi orqali baholashi mumkin.
Calidi Biotherapeutics raqobatchilari
ONC (BeiGene Ltd.) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori HALO (Halozyme Inc.)|RVMD - Narx-foyda va o‘sish multiplikatori|AAPG: Narx-foyda va o‘sish multiplikatori|CGON - PEG multiplikatori|UroGen Pharma (URGN) - Narxning foydaga va o‘sish sur’atiga nisbati|Bicara Therapeutics Inc - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PSNL (Personalis Corp) - PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda Erasca Oncology ERAS|PEG multiplikatori DCTH|Narx-foyda va o‘sish multiplikatori ymabs.com YMAB|PEG multiplikatori AURA (Aura Biosciences)|PEG multiplikatori Candel Therapeutics Inc. CADL|ARAY - Narxning foydaga va o‘sish sur’atiga nisbati|SLS: Narxning foydaga va o‘sish sur’atiga nisbati|ACTU: PEG multiplikatori|CTOR - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|HURA (TuHURA Biosciences Inc.) - PEG multiplikatori|O‘sishni hisobga olgan narx-foyda koeffitsiyenti TARA (Protara Therapeutics Inc)|PEG multiplikatori FATE|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati aadibio.com|TScan Therapeutics, Inc. - Narx-foyda va o‘sish multiplikatori|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti CSBR|XBiotech USA - PEG multiplikatori|CVM: Narxning foydaga va o‘sish sur’atiga nisbati|OSTX: PEG multiplikatori|RADX - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga va o‘sish sur’atiga nisbati Artiva Biotherapeutics Inc.|O‘sish sur’atiga tuzatilgan narx-foyda Adlai Nortye Limited ANL|Narx-foyda va o‘sish multiplikatori VERU (Veru)|Kompaniya qiymatining foyda o‘sish sur’atiga nisbati TPST|PEG multiplikatori XLO (Xilio Therapeutics)|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti RENB|Mural Bio - PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda Kairos Pharma Ltd|onkuretherapeutics.com (OKUR) - Narxning foydaga va o‘sish sur’atiga nisbati|CytoMed Therapeutics Limited - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|CRIS (Curis Inc.) - PEG multiplikatori|PEG multiplikatori Apollomics Corp|Narxning foydaga va o‘sish sur’atiga nisbati Tharimmune, Inc. (THAR)|ADVB: Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati|PEG multiplikatori GNPX (Genprex)|Sunshine Biopharma Inc. (SBFM) - O‘sish sur’atiga tuzatilgan narx-foyda|XBIO: Narx-foyda va o‘sish multiplikatori|SLRX - PEG multiplikatori|PPBT (Purple Biotech) - Narx-foyda va o‘sish multiplikatori|AONC: Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|BGNE (BeiGene) - PEG multiplikatori|Checkpoint Therapeutics Inc. (CKPT) - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|PEG multiplikatori ELEV|Narx-foyda va o‘sish multiplikatori icadmed.com ICAD|Narxning foydaga va o‘sish sur’atiga nisbati Ikena Oncology IKNA|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati notablelabs.com (NTBL)|Viracta - PEG multiplikatori|MorphoSys Inc (MOR) - Narx-foyda va o‘sish multiplikatori|NAYA Bio (NAYA) - Narxning foydaga va o‘sish sur’atiga nisbati|AAPGV (Ascentage) - Narxning foydaga va o‘sish sur’atiga nisbati
